Skip to content

Journal · Pharmacogenomics · Updated 20 November 2026

The Pharmacogenomics Journal

Read The Pharmacogenomics Journal articles on DeepDyve. No university library needed.

The Pharmacogenomics Journal has published since 2001 and covers how genetic differences shape people’s responses to drugs, from gene variants that guide transplant and psychiatric dosing to the costs and clinical use of genetic testing. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of The Pharmacogenomics Journal
November 2026 issue

The Pharmacogenomics Journal at a glance

Full title
The Pharmacogenomics Journal
Abbreviation (NLM)
Pharmacogenomics J
Publisher
Springer Nature
Print ISSN
1470-269X
Online ISSN (eISSN)
1473-1150
First published
2001
Subjects
Molecular Biology, Pharmacology
Access model
Hybrid (60% free to read in 2026)

Ways to access The Pharmacogenomics Journal

60% of the articles The Pharmacogenomics Journal published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 60% of The Pharmacogenomics Journal articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central.
  3. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  4. A library. Your university, hospital or public library may subscribe to The Pharmacogenomics Journal. Check its journal list and whether it offers remote access.
  5. DeepDyve. Read The Pharmacogenomics Journal articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Recent Pharmacogenomics Journal research worth reading

Published January to April 2026. Summaries describe what the authors report.

  1. Open accessPsychiatry · Clinician education

    Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needs

    Surveying 128 mental health clinicians in England, the authors report positive attitudes towards pharmacogenomic testing but little confidence in ordering and interpreting tests, with only 6% answering all four knowledge questions correctly, and they suggest tailored education programmes.

    Panconesi et al. · The Pharmacogenomics Journal, published online January 20, 2026 · DOI 10.1038/s41397-025-00394-x

  2. Open accessPsychiatry · Health economics

    Economic effectiveness of pharmacogenomics-guided prescribing for psychiatric disorders: a systematic review and meta-analysis

    Reviewing 17 studies, the authors report that 88% favoured pharmacogenomics-guided prescribing in psychiatry, while pooled incremental net benefits were positive but not statistically significant, and conclude that it can be cost-effective but economic modelling methods need more consensus.

    Mason et al. · The Pharmacogenomics Journal, published online April 4, 2026 · DOI 10.1038/s41397-026-00408-2

  3. LitStreamColorectal cancer · Chemotherapy response

    Tumour immune cell infiltration and response to FOLFOX or FOLFIRI chemotherapy in colorectal cancer

    Analyzing tumour transcriptomes from 511 colorectal cancer patients, the authors report that M1 macrophage infiltration was linked to better response to FOLFOX, while gamma delta T cells were linked to poorer response and survival, and identify an immune subtype that did better on FOLFIRI.

    Feng et al. · The Pharmacogenomics Journal, published online March 12, 2026 · DOI 10.1038/s41397-026-00403-7

  4. LitStreamKidney transplantation · Tacrolimus

    Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients

    In 94 Greek kidney transplant recipients, the authors report that CYP3A5 expressers carrying CYP3A4*1B or *1G had consistently lower dose-adjusted tacrolimus trough levels than nonexpressers, suggesting that combined CYP3A phenotypes could improve tacrolimus dosing decisions.

    Tsironi et al. · The Pharmacogenomics Journal, published online January 6, 2026 · DOI 10.1038/s41397-025-00395-w

  5. LitStreamDepression · Genetic testing

    A pilot study of pharmacogenomic testing as a tool to enhance depression care in Veterans

    In a 12-week pilot trial of 60 depressed Veterans on several psychiatric drugs, the authors report that targeted pharmacogenomic testing found actionable gene-drug interactions in 30%, compared with 20% in earlier research, but did not change depression scores or medication changes.

    Kennedy et al. · The Pharmacogenomics Journal, published online April 14, 2026 · DOI 10.1038/s41397-026-00406-4

See every The Pharmacogenomics Journal article on DeepDyve

Questions about The Pharmacogenomics Journal

How can I read The Pharmacogenomics Journal articles without a subscription?

60% of The Pharmacogenomics Journal articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central. Your library may also subscribe. DeepDyve lets you read The Pharmacogenomics Journal articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for The Pharmacogenomics Journal?

The Pharmacogenomics Journal’s NLM (PubMed) abbreviation is Pharmacogenomics J.

What is the ISSN of The Pharmacogenomics Journal?

The print ISSN is 1470-269X and the online ISSN is 1473-1150.

Is The Pharmacogenomics Journal open access?

The Pharmacogenomics Journal is a hybrid journal: authors can choose to publish open access or under the subscription model. From January 1 to November 19, 2026, 25 of 42 The Pharmacogenomics Journal articles (60%) carry a Creative Commons license, per Crossref.

The Pharmacogenomics Journal articles on DeepDyve are licensed from Springer Nature. Journal facts as of 20 November 2026.

Start reading The Pharmacogenomics Journal today

One month free, then less than $2 a day. The Pharmacogenomics Journal, plus millions of articles from thousands of journals.

Start free month

Like this: